<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39081653</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-963X</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JACC. Advances</Title><ISOAbbreviation>JACC Adv</ISOAbbreviation></Journal><ArticleTitle>Post-COVID Condition in Patients With Cardiovascular Disease: Are Antivirals the Answer?</ArticleTitle><Pagination><StartPage>100962</StartPage><MedlinePgn>100962</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100962</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacadv.2024.100962</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D&#x119;bski</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Norwich Medical School, University of East Anglia, Norwich, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsampasian</LastName><ForeName>Vasiliki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Norwich Medical School, University of East Anglia, Norwich, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vassiliou</LastName><ForeName>Vassilios S</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Norwich Medical School, University of East Anglia, Norwich, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Adv</MedlineTA><NlmUniqueID>9918419284106676</NlmUniqueID><ISSNLinking>2772-963X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>doi: 10.1016/j.jacadv.2024.100961</RefSource></CommentsCorrections></CommentsCorrectionsList><OtherAbstract Type="Publisher" Language="eng"><AbstractText>[Figure: see text]</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">healthcare utilization</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">nirmatrelvir-ritonavir</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2 infection</Keyword></KeywordList><CoiStatement>Dr D&#x119;bski is supported by United Kingdom National Institute for Health and Care Research (NIHR) as a Clinical Lecturer, award number CL 2022-15-002. Dr Tsampasian is supported by an 10.13039/100006662NIHR Doctoral Research Fellowship award number 303306. Dr Vassiliou has reported that he has no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39081653</ArticleId><ArticleId IdType="pmc">PMC11286977</ArticleId><ArticleId IdType="doi">10.1016/j.jacadv.2024.100962</ArticleId><ArticleId IdType="pii">S2772-963X(24)00147-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdelaziz H.K., Abdelrahman A., Nabi A., et al. Impact of COVID-19 pandemic on patients with ST-segment elevation myocardial infarction: insights from a British Cardiac Center. Am Heart J. 2020;226:45&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211651</ArticleId><ArticleId IdType="pubmed">32497914</ArticleId></ArticleIdList></Reference><Reference><Citation>Debski M., Abdelaziz H.K., Sanderson J., et al. Mental health outcomes among British Healthcare Workers-lessons from the first wave of the covid-19 Pandemic. J&#xa0;Occup Environ Med. 2021;63:e549&#x2013;e555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8327764</ArticleId><ArticleId IdType="pubmed">34190508</ArticleId></ArticleIdList></Reference><Reference><Citation>Baral R., Tsampasian V., Debski M., et al. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19. JAMA Netw Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013817</ArticleId><ArticleId IdType="pubmed">33787911</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  A&#xa0;clinical case definition of post COVID-19 condition by a Delphi Consensus. https://iris.who.int/handle/10665/345824</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Bowe B., Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun. 2021;12:6571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., van Zon S.K.R., Olde Hartman T.C., Rosmalen J.G.M. Persistence of somatic symptoms after COVID-19 in The Netherlands: an Observational Cohort Study. Lancet. 2022;400:452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Debski M., Tsampasian V., Haney S., et al. Post-COVID-19 syndrome risk factors and further use of health services in East England. PLOS Glob Public Health. 2022;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10022108</ArticleId><ArticleId IdType="pubmed">36962824</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V., Elghazaly H., Chattopadhyay R., et al. Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023;183:566&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V., Back M., Bernardi M., et al. Cardiovascular disease as part of Long COVID: a systematic review. Eur J Prev Cardiol. 2024 doi: 10.1093/eurjpc/zwae070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurjpc/zwae070</ArticleId><ArticleId IdType="pubmed">38381595</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y.J., Seo Y.B., Seo J.-W., et al. Effectiveness of antiviral therapy on long COVID: a systematic review and meta-analysis. J&#xa0;Clin Med. 2023;12:7375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10707593</ArticleId><ArticleId IdType="pubmed">38068427</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R., Dani S.S., Khadke S., et al. Nirmatrelvir-ritonavir for acute COVID-19 in patients with cardiovascular disease and postacute sequelae of SARS-CoV-2-infection. JACC: Adv. 2024;3</Citation></Reference><Reference><Citation>Food and Drug Administration integrated review of new drug application (number 217188) for nirmatrelvir and ritonavir. Version 3.0 (05/25/2022) https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217188Orig1s000IntegratedR.pdf</Citation></Reference><Reference><Citation>COVID-19 Treatment Guidelines Panel  Coronavirus disease 2019 (COVID-19) treatment guidelines. Drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and concomitant medications. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir&#x2013;paxlovid-/paxlovid-drug-drug-interactions</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>